European Commission Approves the First and Only Immuno-Oncology Combination, Bristol-Myers Squibb’s Opdivo (nivolumab) + Yervoy (ipilimumab) Regimen, for Treatment of Advanced Melanoma
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
|BMY||Community voting in process|
Slingshot Insights Explained
Don’t see a project related to the catalyst you care about?